Nutex Health (NUTX) Q3 2026 Earnings Call Transcript

Nutex Health reported first-nine-month 2026 revenue of $644.9 million, down 10.9% year over year, and adjusted EBITDA of $211.4 million, down 13%; management attributed much of the decline to unusually high 2025 revenue recognition. Net income rose 159% to $152.9 million, hospital visits increased 10.2%, and cash reached $249.9 million at Sept. 30. Management cited continued growth and planned two hospital openings by year-end, while warning that physician collections were slightly softer and opposing a proposed bill that would eliminate the IDR process beginning in 2028.

Analysis

The key issue is earnings quality, not reported net income: the sharp decline in legacy earn-out stock compensation and a non-cash contract-services credit flatter GAAP profit, while adjusted EBITDA fell and facility costs rose as a share of revenue. Volume growth is encouraging, but it has not yet offset revenue normalization per visit. A further tell is the emerging softness in physician collections while hospital collections remain steadier; if that persists, consolidated revenue and cash conversion may weaken even with higher visits. Rising receivables warrant checking aging and subsequent cash receipts rather than treating operating cash flow as proof that payer risk is contained.

NUTX’s IDR economics remain the central valuation dependency. A four-to-six-month resolution cycle ties up working capital, and reported award win/collection rates are management-reported, with collection data only through March 2026. Stronger upfront payer reimbursement could reduce disputes but also lower realized revenue per visit; weaker payer compliance instead raises delay and bad-debt risk. The proposed 2028 elimination of IDR is a material tail risk, but passage is uncertain and not an immediate base-case catalyst. The Murphy proposal could support collections if enacted; litigation and audits are supportive signals, not assured changes in payer behavior.

Near term, openings and visit trends may support sentiment; over 1–3 months, watch quarterly revenue per visit, physician collections, receivable aging, and whether margins stabilize. Over 6–18 months, construction spending and added debt compete with cash returns, while legislation shapes the multiple. Contrarian point: volume growth is not automatically high-quality growth when reimbursement remains delayed and recognition-dependent. Without current valuation, share-price levels, and a clean filing reconciliation, the call does not justify a fresh directional position.

Key Decisions for Investors

• No immediate directional trade in NUTX; first reconcile the call’s apparent transcript inconsistencies against the 10-Q and confirm receivable aging, cash receipts after quarter-end, and physician-versus-hospital collection trends.
• Set a 1–3 month alert: reconsider a small long only if revenue per visit stabilizes near the company’s stated historical range, physician collections stop deteriorating, and same-hospital volume growth converts into steadier adjusted EBITDA. Falsify this setup if collections weaken further or facility margins continue compressing.
• Treat IDR legislation as a downside scenario, not a certainty: track bill progress and payer compliance. A credible path to eliminating IDR before 2028, or a sustained fall in award collections, would warrant reducing exposure; enacted enforcement improvements with faster cash realization would improve the thesis.
• Monitor the two near-term openings and later construction for capex, opening delays, and incremental debt. Cash provides flexibility, but expansion only adds value if new facilities ramp without diluting operating cash conversion; avoid extrapolating current cash balances into a durable capital-return case.